Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.71 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | THPO | P40225 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | APEX1 | P27695 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Histidine SCHEMBL28403793 | 0.97 | CYP3A4 (0.71) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| Histidine SCHEMBL30535770 | 0.97 | CYP3A4 (0.71) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| Histidine SCHEMBL26659431 | 0.97 | CYP3A4 (0.71) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| Histidine SCHEMBL30039286 | 0.97 | CYP3A4 (0.71) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| Histidine SCHEMBL19974306 | 0.83 | CYP3A4 (1.00) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL5497653 | 0.83 | CYP3A4 (0.75) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| Histidine SCHEMBL30852263 | 0.83 | CYP3A4 (1.00) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| D-Histidine SCHEMBL288043 | 0.83 | CYP3A4 (1.00) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL5717709 | 0.83 | CYP3A4 (0.75) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| Histidine SCHEMBL388560 | 0.83 | CYP3A4 (1.00) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260041714-A1 | CROSS-LINKING AGENTS AND ASSOCIATED METHODS | UNIV UTAH RES FOUND (US) | 2026-02-12 | — | — | US | claimed |
| US-12544400-B2 | Treatment of myopic progression | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2026-02-10 | — | — | US | claimed |
| US-20240091255-A1 | TREATMENT OF ASTIGMATISM | IVEENA DELIVERY SYSTEMS, INC. | 2024-03-21 | — | — | US | claimed |
| EP-4324454-A2 | CROSS-LINKING AGENTS AND ASSOCIATED METHODS | University of Utah Research Foundation (US) | 2024-02-21 | — | — | EP | claimed |
| EP-4284392-A1 | TREATMENT OF ASTIGMATISM | Iveena Delivery Systems, Inc. (US) | 2023-12-06 | — | — | EP | claimed |
| EP-3426262-B1 | CROSS-LINKING AGENTS AND ASSOCIATED METHODS | UNIV UTAH RES FOUND (US) | 2023-08-23 | — | — | EP | claimed |
| US-20230256012-A1 | TREATMENT OF MYOPIC PROGRESSION | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2023-08-17 | — | — | US | claimed |
| US-11524032-B2 | Treatment of myopic progression | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2022-12-13 | — | — | US | claimed |
| US-20220288114-A1 | MULTI-AGENT OCULAR FORMULATIONS AND TREATMENT METHODS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2022-09-15 | — | — | US | claimed |
| CN-108431216-B | Codon-optimized reduced size ATP7A CDNA and use for treating copper transport disorders | 美国政府(由卫生和人类服务部的部长所代表) | 2022-08-05 | — | — | CN | claimed |
| WO-2022165098-A1 | TREATMENT OF ASTIGMATISM | IVEENA DELIVERY SYSTEMS, INC. (US) | 2022-08-04 | — | — | WO | claimed |
| EP-3996644-A1 | MULTI-AGENT OCULAR FORMULATIONS AND TREATMENT METHODS | University of Utah Research Foundation (US) | 2022-05-18 | — | — | EP | claimed |
| US-20260137604-A1 | COSMETIC COMPOSITIONS | L'OREAL (FR) | 2026-05-21 | — | — | US | disclosed |
| US-20260041714-A1 | CROSS-LINKING AGENTS AND ASSOCIATED METHODS | UNIV UTAH RES FOUND (US) | 2026-02-12 | — | — | US | disclosed |
| US-12544400-B2 | Treatment of myopic progression | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2026-02-10 | — | — | US | disclosed |
| US-20250388908-A1 | METAL HOMEOSTASIS REGULATION | WORCESTER POLYTECH INST (US) | 2025-12-25 | — | — | US | disclosed |
| EP-3996644-A1 | MULTI-AGENT OCULAR FORMULATIONS AND TREATMENT METHODS | University of Utah Research Foundation (US) | 2022-05-18 | — | — | EP | disclosed |
| EP-3981392-A1 | CONTROLLED RELEASE DOSAGE FORM | Triastek, Inc. (CN) | 2022-04-13 | — | — | EP | disclosed |
| US-11278499-B2 | Oral drug dosage form comprising various release profiles | Triastek, Inc. (CN) | 2022-03-22 | — | — | US | disclosed |
| US-20220054409-A1 | RAPIDLY-ORODISPERSIBLE TABLETS HAVING AN INTERIOR CAVITY | Aprecia Pharmaceuticals LLC | 2022-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388908-A1 | METAL HOMEOSTASIS REGULATION | SLC39A14, SLC39A11, SLC39A3 | CYP3A4 2454/4885SLC7A5 173/4885HRH4 4723/4885 |
| US-20260041714-A1 | CROSS-LINKING AGENTS AND ASSOCIATED METHODS | KCNK17, KCNJ2, KCNK2 | CYP3A4 3372/4885SLC7A5 1683/4885HRH4 4670/4885 |
| US-11278499-B2 | Oral drug dosage form comprising various release profiles | CYP2D6, CYP3A7, CYP3A5 | CYP3A4 4/4885SLC7A5 62/4885HRH4 1133/4885 |
| US-20260137604-A1 | COSMETIC COMPOSITIONS | TYR, CUTA, LAGE3 | CYP3A4 4034/4885SLC7A5 1105/4885HRH4 4023/4885 |
| US-12544400-B2 | Treatment of myopic progression | LOXL1, LOXL3, LOXL2 | CYP3A4 2783/4885SLC7A5 811/4885HRH4 4059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.